ArticleJournal of inherited metabolic disease2008
Adalimumab for the treatment of Crohn-like colitis and enteritis in glycogen storage disease type Ib.
Article in Journal of inherited metabolic disease, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- [Clinical analysis and follow-up outcomes of 25 pediatric cases with hepatic glycogen storage disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Empagliflozin in children with glycogen storage disease-associated inflammatory bowel disease: a prospective, single-arm, open-label clinical trial.Scientific reports · 2024Article
- Glycogen storage diseases: An update.World journal of gastroenterology · 2023Review
- Infliximab treatment of glycogenosis Ib with Crohn's-like enterocolitis: A case report.World journal of clinical cases · 2021Article
- Infectious and digestive complications in glycogen storage disease type Ib: Study of a French cohort.Molecular genetics and metabolism reports · 2020Article
- Remission of Inflammatory Bowel Disease in Glucose-6-Phosphatase 3 Deficiency by Allogeneic Haematopoietic Stem Cell Transplantation.Journal of Crohn's & colitis · 2020Article
- Mutation analysis ofThe Journal of international medical research · 2019Article
- The role of monogenic disease in children with very early onset inflammatory bowel disease.Current opinion in pediatrics · 2017Review
- Maintaining intestinal health: the genetics and immunology of very early onset inflammatory bowel disease.Cellular and molecular gastroenterology and hepatology · 2015Article
- The diagnostic approach to monogenic very early onset inflammatory bowel disease.Gastroenterology · 2014Review
- Glucose-6-phosphatase deficiency.Orphanet journal of rare diseases · 2011Review
- Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy.Nature reviews. Endocrinology · 2010Review
- Pregnancy in glycogen storage disease type Ib: gestational care and report of first successful deliveries.Journal of inherited metabolic disease · 2010Article
- Antibodies to CBir1 are associated with glycogen storage disease type Ib.Journal of pediatric gastroenterology and nutrition · 2010Article
- Adalimumab for the treatment of Crohn's disease.Biologics : targets & therapy · 2008Article
- Genomic and Immunologic Drivers of Very Early-Onset Inflammatory Bowel Disease.Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology SocietyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glycogen storage disease (GSD) type Ib is a congenital disorder of glycogen metabolism that is associated with neutropenia, neutrophil dysfunction, and an inflammatory bowel disease that mimics a Crohn phenotype. Gastrointestinal inflammation in GSD Ib has been successfully treated with 5-aminosalicylic acid and granulocyte colony-stimulating factor (G-CSF). However, therapeutic options for patients not responding to traditional therapies have been limited owing to untoward effects of glucocorticoids and immunomodulators in this metabolic disorder. Adalimumab is a monoclonal antibody targeting tumour necrosis factor-α that has shown promise for the treatment of patients with Crohn disease. Due to the limited options for treating GSD-associated inflammatory bowel disease, use of adalimumab was attempted in a case unresponsive to aminosalicylate, G-CSF, and antibiotic therapy. Significant clinical and histological improvement was observed in our patient, and the medication was well tolerated.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.